RxDoctor Payments DataLook up a doctor →

Samuel Kantor, MD

Nephrology · Las Vegas, NVNPI 1316909864

Payments from drug & device makers

$1,015,152in general payments, 2019–2025

Across 1,862 payments — averaging $545.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$285K
  • Boehringer Ingelheim$152K
  • Akebia Therapeutics Inc$151K
  • AstraZeneca$108K
  • Amgen$90K
  • Novartis$82K
  • plus $147K from 44 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK119$284,653
Boehringer Ingelheim33$152,095
Akebia Therapeutics Inc181$151,443
AstraZeneca(2 entities)260$108,307
Amgen(2 entities)235$89,789
Novartis50$81,864
Bayer110$43,708
Vifor Pharma, Inc.164$26,753
Fresenius USA Marketing, Inc.177$25,025
Calliditas Therapeutics US Inc.48$14,395
AbbVie(2 entities)2$12,643
Otsuka Pharmaceutical Development & Commercialization, Inc.12$6,109
Boehringer Ingelheim Limited5$3,638
Otsuka America Pharmaceutical, Inc.81$2,075
Daiichi Sankyo Inc.94$1,522
Johnson & Johnson11$1,379
OPKO Pharmaceuticals, LLC66$1,344
Novo Nordisk39$1,328
Aurinia Pharma U.S., Inc.19$1,230
Travere Therapeutics, Inc.32$1,213
Lilly USA, LLC17$466
Ardelyx, Inc.16$395
Amarin Pharma, Inc.15$362
Mallinckrodt Hospital Products Inc.9$318
Kyowa Kirin, Inc.8$254
Sanofi3$251
Sanofi-aventis U.S. LLC3$237
Shire North American Group Inc2$229
Biogen2$219
Ultragenyx Pharmaceutical Inc.4$177
Merck5$167
Apellis Pharmaceuticals, Inc.3$165
Pharmacosmos Therapeutics Inc.7$159
Genentech USA, Inc.4$157
ANI Pharmaceuticals, Inc.5$132
Corcept Therapeutics1$127
Gilead1$124
Ipsen Biopharmaceuticals, Inc1$117
Takeda Pharmaceuticals U.S.A., Inc.6$112
Viiv Healthcare Company1$112
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$104
Fujifilm Wako Diagnostics U.S.A. Corporation1$101
Amicus Therapeutics, Inc.2$45
Shield Therapeutics Inc1$23
Azurity Pharmaceuticals, Inc.1$21
Arbor Pharmaceuticals, Inc.1$18
Boston Scientific1$17
Alnylam Pharmaceuticals Inc.1$15
Cormedix Inc.1$14
Boehringer Ingelheim International GmbH1$3

How this compares

$1,015,152 in reported general payments places this provider in the 95th percentile of 125 nephrology providers in Nevada.

See all nephrology providers in Nevada →

Medicare billing

Part B allowed, 2024
$170,204
Medicare patients
496
Services billed
1,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →